肾细胞癌治疗的最新进展。
Recent developments in the treatment of renal cell carcinoma.
机构信息
Associate Director, Cancer Research Foundation, Immediate Past Chair of ECOG-ACRIN Renal Cancer Subcommittee, 750 Kappock Street, # 511, Bronx, NY 10463, USA.
出版信息
Ther Adv Urol. 2013 Dec;5(6):338-53. doi: 10.1177/1756287213505672.
Abstract
Renal cell carcinoma (RCC) management has been imbued with new interest, in large part due to the recent success of new treatment options for advanced and metastatic disease. This has also been accompanied by less generally well known advances in the understanding of the molecular characterizations of subtypes of RCC with potential to lead to new therapeutic options. Additionally, the urologic oncology community is focusing on nephron-sparing surgical approaches with limited surgery if possible, and in conjunction with interventional radiologists, on ablative procedures for incidentally determined small renal masses. This report reviews some of the new biologic findings of adenocarcinoma of the kidney, and reviews the new therapeutics which continue to change the landscape for treatment of RCC.
摘要
肾细胞癌（RCC）的治疗一直备受关注，这在很大程度上是由于最近在晚期和转移性疾病的新治疗选择方面取得了成功。与此同时，人们对 RCC 亚型的分子特征的理解也取得了一些不太广为人知的进展，这有可能为新的治疗选择提供依据。此外，泌尿科肿瘤学领域的研究人员正在关注保留肾单位的手术方法，如果可能的话，尽量减少手术，并与介入放射科医生合作，对偶然发现的小肾肿瘤进行消融治疗。本报告回顾了肾腺癌的一些新的生物学发现，并回顾了不断改变 RCC 治疗格局的新疗法。
相似文献
1
Recent developments in the treatment of renal cell carcinoma.肾细胞癌治疗的最新进展。
Ther Adv Urol. 2013 Dec;5(6):338-53. doi: 10.1177/1756287213505672.
2
Molecular insight into renal cancer and latest therapeutic approaches to tackle it: an updated review.肾癌的分子洞察及最新治疗方法：一篇更新综述
Med Oncol. 2023 Nov 13;40(12):355. doi: 10.1007/s12032-023-02225-0.
3
Evaluation and management of the renal mass.肾脏肿块的评估和处理。
Med Clin North Am. 2011 Jan;95(1):179-89. doi: 10.1016/j.mcna.2010.08.021.
4
Current management of renal cell carcinoma and targeted therapy.肾细胞癌的当前管理与靶向治疗。
Urol J. 2006 Winter;3(1):1-14.
5
Identification and validation of novel prognostic markers in Renal Cell Carcinoma.肾细胞癌中新型预后标志物的鉴定与验证
Dan Med J. 2017 Oct;64(10).
6
Novel approaches in the therapy of metastatic renal cell carcinoma.转移性肾细胞癌治疗的新方法。
World J Urol. 2005 Jul;23(3):202-12. doi: 10.1007/s00345-004-0466-0. Epub 2005 Apr 5.
7
Surgical management of renal cell carcinoma.肾细胞癌的外科治疗
Semin Oncol. 2006 Oct;33(5):552-62. doi: 10.1053/j.seminoncol.2006.06.007.
8
Changing concepts in the surgical management of renal cell carcinoma.肾细胞癌外科治疗观念的转变
Eur Urol. 2004 Jun;45(6):692-705. doi: 10.1016/j.eururo.2004.02.002.
9
Nephron sparing surgery for renal tumors: indications, techniques and outcomes.肾肿瘤的保留肾单位手术：适应证、技术及疗效
J Urol. 2001 Jul;166(1):6-18.
10
Treatment of advanced renal cell carcinoma: recent advances and current role of immunotherapy, surgery, and cryotherapy.晚期肾细胞癌的治疗：免疫疗法、手术及冷冻疗法的最新进展与当前作用
Tumori. 2017 Jan 21;103(1):15-21. doi: 10.5301/tj.5000581. Epub 2016 Oct 26.
引用本文的文献
1
NUTM2A-AS1 as a potential key regulator in cancer: unraveling its ceRNA networks and impact on tumor biology.NUTM2A-AS1作为癌症中的潜在关键调节因子：揭示其ceRNA网络及其对肿瘤生物学的影响
Eur J Med Res. 2025 Sep 3;30(1):840. doi: 10.1186/s40001-025-03019-y.
2
3
DNA vaccines as promising immuno-therapeutics against cancer: a new insight.DNA疫苗作为有前景的癌症免疫疗法：新见解
Front Immunol. 2025 Jan 13;15:1498431. doi: 10.3389/fimmu.2024.1498431. eCollection 2024.
4
Affinity fine-tuning anti-CAIX CAR-T cells mitigate on-target off-tumor side effects.亲和力微调抗 CAIX CAR-T 细胞减轻靶标外脱靶肿瘤副作用。
Mol Cancer. 2024 Mar 16;23(1):56. doi: 10.1186/s12943-024-01952-w.
5
Evolution of cell therapy for renal cell carcinoma.细胞治疗肾细胞癌的进展。
Mol Cancer. 2024 Jan 9;23(1):8. doi: 10.1186/s12943-023-01911-x.
6
A Cuproptosis-Related Gene Model For Predicting the Prognosis of Clear Cell Renal Cell Carcinoma.一种用于预测透明细胞肾细胞癌预后的铜死亡相关基因模型
Front Genet. 2022 Aug 11;13:905518. doi: 10.3389/fgene.2022.905518. eCollection 2022.
7
Radiotherapy and High-Dose Interleukin-2: Clinical and Immunological Results of a Proof of Principle Study in Metastatic Melanoma and Renal Cell Carcinoma.放疗和高剂量白细胞介素-2：转移性黑色素瘤和肾细胞癌原理研究的临床和免疫学结果。
Front Immunol. 2021 Oct 27;12:778459. doi: 10.3389/fimmu.2021.778459. eCollection 2021.
8
Effect of Aberrant Long Noncoding RNA on the Prognosis of Clear Cell Renal Cell Carcinoma.异常长链非编码 RNA 对透明细胞肾细胞癌预后的影响。
Comput Math Methods Med. 2021 Sep 3;2021:6533049. doi: 10.1155/2021/6533049. eCollection 2021.
9
miR-129-5p inhibits clear cell renal cell carcinoma cell proliferation, migration and invasion by targeting SPN.微小RNA-129-5p通过靶向丝氨酸蛋白酶抑制剂（SPN）抑制肾透明细胞癌细胞的增殖、迁移和侵袭。
Cancer Cell Int. 2021 May 17;21(1):263. doi: 10.1186/s12935-021-01820-3.
10
Biological Evaluation of Oxindole Derivative as a Novel Anticancer Agent against Human Kidney Carcinoma Cells.吲哚酮衍生物作为新型抗癌剂对人肾癌细胞的生物学评价。
Biomolecules. 2020 Aug 31;10(9):1260. doi: 10.3390/biom10091260.
本文引用的文献
1
BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma--A Trial of the ECOG-ACRIN Cancer Research Group (E2804).BEST：血管内皮生长因子、RAF激酶和雷帕霉素哺乳动物靶点联合靶向治疗（贝伐单抗、索拉非尼和替西罗莫司）用于晚期肾细胞癌的随机II期研究——东部肿瘤协作组-美国放射肿瘤学会癌症研究组（E2804）试验
J Clin Oncol. 2015 Jul 20;33(21):2384-91. doi: 10.1200/JCO.2015.60.9727. Epub 2015 Jun 15.
2
RECORD-2: phase II randomized study of everolimus and bevacizumab versus interferon α-2a and bevacizumab as first-line therapy in patients with metastatic renal cell carcinoma.记录 2：依维莫司和贝伐珠单抗与干扰素 α-2a 和贝伐珠单抗作为转移性肾细胞癌一线治疗的 II 期随机研究。
Ann Oncol. 2015 Jul;26(7):1378-84. doi: 10.1093/annonc/mdv170. Epub 2015 Apr 7.
3
Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial.随机 III 期试验：替西罗莫司联合贝伐珠单抗与干扰素 α 联合贝伐珠单抗治疗转移性肾细胞癌：INTORACT 试验。
J Clin Oncol. 2014 Mar 10;32(8):752-9. doi: 10.1200/JCO.2013.50.5305. Epub 2013 Dec 2.
4
Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial.替沃扎尼布与索拉非尼作为转移性肾细胞癌患者的初始靶向治疗：III 期试验结果。
J Clin Oncol. 2013 Oct 20;31(30):3791-9. doi: 10.1200/JCO.2012.47.4940. Epub 2013 Sep 9.
5
Nivolumab plus ipilimumab in advanced melanoma.纳武利尤单抗联合伊匹单抗治疗晚期黑色素瘤。
N Engl J Med. 2013 Jul 11;369(2):122-33. doi: 10.1056/NEJMoa1302369. Epub 2013 Jun 2.
6
Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial.阿昔替尼对比索拉非尼作为晚期肾细胞癌的二线治疗：一项随机 3 期临床试验的总生存分析及更新结果。
Lancet Oncol. 2013 May;14(6):552-62. doi: 10.1016/S1470-2045(13)70093-7. Epub 2013 Apr 16.
7
Sunitinib in combination with gemcitabine for advanced solid tumours: a phase I dose-finding study.舒尼替尼联合吉西他滨治疗晚期实体瘤的 I 期剂量递增研究。
Br J Cancer. 2013 Apr 16;108(7):1393-401. doi: 10.1038/bjc.2013.96. Epub 2013 Mar 19.
8
Single-dose cyclophosphamide synergizes with immune responses to the renal cell cancer vaccine IMA901.单剂量环磷酰胺可增强对肾细胞癌疫苗IMA901的免疫反应。
Oncoimmunology. 2013 Jan 1;2(1):e22246. doi: 10.4161/onci.22246.
9
Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib.比较 mTOR、PI3K 及双重 PI3K/mTOR 抑制剂在对舒尼替尼和索拉非尼产生耐药的肝癌和肾癌模型中的疗效。
Cancer Chemother Pharmacol. 2013 May;71(5):1297-307. doi: 10.1007/s00280-013-2129-6. Epub 2013 Mar 12.
10
Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer.抗 PD-1 和 B7-H1（PD-L1）抗体在治疗晚期人类癌症中的应用。
Clin Cancer Res. 2013 Mar 1;19(5):1021-34. doi: 10.1158/1078-0432.CCR-12-2063.
Zotero 插件